{"id":21768,"date":"2022-03-02T11:47:42","date_gmt":"2022-03-02T09:47:42","guid":{"rendered":"https:\/\/vilkaviskiovsb.lt\/?p=21768"},"modified":"2022-03-02T11:47:42","modified_gmt":"2022-03-02T09:47:42","slug":"lietuva-pasieke-nauja-vakcina-nuo-covid-19-ligos","status":"publish","type":"post","link":"https:\/\/vilkaviskiovsb.lt\/en\/2022\/03\/02\/lietuva-pasieke-nauja-vakcina-nuo-covid-19-ligos\/","title":{"rendered":"Lietuv\u0105 pasiek\u0117 nauja vakcina nuo COVID-19 ligos"},"content":{"rendered":"<p><strong><img data-recalc-dims=\"1\" loading=\"lazy\" decoding=\"async\" class=\"aligncenter wp-image-21769 size-full\" src=\"https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19905_8b003020dab758745b472a8a74feed75.jpg?resize=852%2C536&#038;ssl=1\" alt=\"\" width=\"852\" height=\"536\" srcset=\"https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19905_8b003020dab758745b472a8a74feed75.jpg?w=852&amp;ssl=1 852w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19905_8b003020dab758745b472a8a74feed75.jpg?resize=300%2C189&amp;ssl=1 300w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19905_8b003020dab758745b472a8a74feed75.jpg?resize=768%2C483&amp;ssl=1 768w, https:\/\/i0.wp.com\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19905_8b003020dab758745b472a8a74feed75.jpg?resize=18%2C12&amp;ssl=1 18w\" sizes=\"auto, (max-width: 852px) 100vw, 852px\" \/>Pirmadien\u012f Lietuv\u0105 pasiek\u0117 pirmoji farmacijos kompanijos \u201eNovavax\u201c sukurtos COVID-19 vakcinos \u201eNuvaxovid\u201c siunta, kuri\u0105 sudaro 45 t\u016bkst. vakcinos dozi\u0173. Per kelias dienas jos bus paskirstytos skiepijan\u010dioms gydymo \u012fstaigoms, registracija skiepijimui \u0161ia vakcina taip pat prasid\u0117s artimiausiomis dienomis.<\/strong><\/p>\n<p>Skiepytis \u201eNuvaxovid\u201c vakcina gali dar nesiskiepij\u0119 gyventojai, sulauk\u0119 18 met\u0173. Vakcina suleid\u017eiama dviem doz\u0117mis, tarp j\u0173 daroma trij\u0173 savai\u010di\u0173 pertrauka. Registruotis skiepijimui \u0161ia ar kitomis vakcinomis nuo COVID-19 ligos galima internetu <a href=\"http:\/\/www.koronastop.lt\/\" target=\"_blank\" rel=\"noopener\">www.koronastop.lt<\/a> arba trumpuoju numeriu 1808.<\/p>\n<p>\u201eNuvaxovid\u201c yra baltym\u0173 pagrindu sukurta vakcina \u2013 tai yra gerai \u017einoma ir daugiau nei 30 met\u0173 naudojama vakcin\u0173 gamybos technologija. Baltym\u0173 pagrindu taip pat yra kuriamos vakcinos nuo hepatito B, kokliu\u0161o ir pneumokokin\u0117s infekcijos.<\/p>\n<p>Klinikiniai tyrimai parod\u0117, kad \u201eNuvaxovid\u201c veiksmingumas apsaugant nuo COVID-19 ligos siekia 90 proc. \u012evertinusi klinikini\u0173 tyrim\u0173, kuriuose dalyvavo 45 t\u016bkst. \u017emoni\u0173, duomenis, Europos vaist\u0173 agent\u016bra 2021 m. gruod\u017eio 20 d. rekomendavo naudoti \u0161i\u0105 vakcin\u0105 pirminiam skiepijimui nuo COVID-19 ligos. Tai yra jau penkta vakcina nuo COVID-19 ligos, patvirtinta Europos S\u0105jungoje.<\/p>\n<p>Ar nauja vakcina bus tinkama sustiprinan\u010diajai dozei, parodys tolesni tyrimai. Gamintojas taip pat \u017ead\u0117jo adaptuoti vakcin\u0105 naujoms nerim\u0105 kelian\u010dioms koronaviruso atmainoms, tokioms kaip omikron. Ta\u010diau jau dabar pastebima, kad \u201eNuvaxovid\u201c u\u017etikrina labai auk\u0161t\u0105 antik\u016bn\u0173 titr\u0105, o tai yra svarbu u\u017etikrinant organizmo apsaug\u0105 nuo nauj\u0173 koronaviruso atmain\u0173.<\/p>\n<p>Europos Komisija pra\u0117jusi\u0173 met\u0173 rugpj\u016b\u010dio 4 d. su kompanija \u201eNovavax\u201c pasira\u0161\u0117 i\u0161ankstin\u0119 pirkimo sutart\u012f, kuri numato galimyb\u0119 ES \u0161alims nar\u0117ms \u012fsigyti iki 100 mln. vakcinos dozi\u0173, o esant papildomam poreikiui \u2013 iki 2023 m. u\u017esakyti dar 100 mln. dozi\u0173.<\/p>\n<p>2022 m. pirm\u0105j\u012f ketvirt\u012f Lietuva tur\u0117t\u0173 gauti 132 000 \u201eNuvaxovid\u201c vakcinos dozi\u0173, antrajam ketvir\u010diui siekiama u\u017esakyti dar 310 560 dozi\u0173. Lietuvos Vyriausyb\u0117 i\u0161 viso yra pritarusi 633 t\u016bkst. vakcinos dozi\u0173 \u012fsigijimui i\u0161 kompanijos \u201eNovavax\u201c.<\/p>\n<p><a href=\"https:\/\/sam.lrv.lt\/lt\/kontaktai-ziniasklaidai\" target=\"_blank\" rel=\"noopener\"><em>SAM Spaudos tarnyba<\/em><\/a><\/p>","protected":false},"excerpt":{"rendered":"<p>Pirmadien\u012f Lietuv\u0105 pasiek\u0117 pirmoji farmacijos kompanijos \u201eNovavax\u201c sukurtos COVID-19 vakcinos \u201eNuvaxovid\u201c siunta, kuri\u0105 sudaro 45 t\u016bkst. vakcinos dozi\u0173. Per kelias dienas jos bus paskirstytos skiepijan\u010dioms gydymo \u012fstaigoms, registracija skiepijimui \u0161ia vakcina taip pat prasid\u0117s artimiausiomis dienomis. Skiepytis \u201eNuvaxovid\u201c vakcina gali dar nesiskiepij\u0119 gyventojai, sulauk\u0119 18 met\u0173. Vakcina suleid\u017eiama dviem doz\u0117mis, tarp j\u0173 daroma trij\u0173 savai\u010di\u0173&hellip;<\/p>","protected":false},"author":15,"featured_media":21769,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[100],"tags":[],"class_list":["post-21768","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-del-covid-19","category-100","description-off"],"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/p7kWFe-5F6","jetpack_featured_media_url":"https:\/\/vilkaviskiovsb.lt\/wp-content\/uploads\/2022\/03\/19905_8b003020dab758745b472a8a74feed75.jpg","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21768","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/comments?post=21768"}],"version-history":[{"count":1,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21768\/revisions"}],"predecessor-version":[{"id":21770,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/posts\/21768\/revisions\/21770"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media\/21769"}],"wp:attachment":[{"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/media?parent=21768"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/categories?post=21768"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vilkaviskiovsb.lt\/en\/wp-json\/wp\/v2\/tags?post=21768"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}